by Stacey Johnson | Nov 25, 2022
If manufacturing is the gatekeeper to success in the cell and gene therapy space, it’s not surprising that the topic regularly comes up when industry leaders come together to discuss the future or to tackle the challenges we face in commercializing cell and gene...
by Josh Dierolf | Oct 4, 2022
The COVID-19 pandemic has been a transformative period for many. Our values and perspectives have been put to the test as schools, workplaces, and day-to-day operations adjusted to the new ways of living. One aspect of the last few years has been coined “The Great...
by Cal Strode | May 26, 2022
In part 1 of this feature marking the 10-year anniversary of Signals, we got to know the people behind the posts a little better. Now, we’re looking to the future of regenerative medicine and science with the help of our contributors. In this post, bloggers Lyla...
by Cal Strode | May 18, 2022
To mark Signals’ 10-year anniversary, we caught up with some of our active current bloggers — Lyla El-Fayomi, David Kent and Sara Nolte — to get to know them a little better, talk science communication and, in next week’s follow-up post, predict what a science-enabled...
by Cal Strode | May 11, 2022
When Signals first burst onto the scene in 2012, the potential of the regenerative medicine industry still hadn’t set in for many. When the Alliance for Regenerative Medicine (ARM) published its first state of the industry report in 2012, the ARM chairman at the time,...
by Stacey Johnson | May 6, 2022
This month is the 10-year anniversary of when Lisa Willemse and I launched Signals. As you would imagine, blogs come and go so 10 years is a significant milestone. It is also my 10-year anniversary at CCRM and when I was introduced to the regenerative medicine field....
Comments